Top

Published in:

Open Access 01-02-2020 | Insulins | Original Contributions

The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats

Authors: Alonso Camacho-Ramírez, J. Arturo Prada-Oliveira, Antonio Ribelles-García, David Almorza-Gomar, Gonzalo M. Pérez-Arana

Published in: Obesity Surgery | Issue 2/2020

Abstract

Aims

Roux-en-Y gastric bypass (RYGB) is one of the most effective surgical therapies for the rapid resolution of type 2 diabetes. However, the mechanisms underlying the entero-hormonal response after surgery and the role of peptide tyrosine tyrosine (PYY) in the restoration of normoglycemia are still not clear.

Methods

We reproduced the RYGB technique in Wistar and Goto–Kakizaki rats and performed serum hormonal, histological, and hormonal-infusion test.

Results

Using the diabetic Goto–Kakizaki (GK) rat model, we demonstrated that PYY plasma levels showed a remarkable peak approximately 30 min earlier than GLP-1 or GIP after mixed-meal administration in RYGB-operated rats with PYY. The GLP-1 and GIP areas under the curve (AUCs) increased after RYGB in GK rats. Additionally, the findings suggested that PYY (3-36) infusion led to increased GLP-1 and GIP plasma levels close to those obtained after a meal. Finally, the number of GLP-1-positive cells appeared to increase in the three segments of the small intestine in GK-RYGB-operated rats beyond the early presence of nutrient stimulation in the ileum. Nevertheless, PYY-positive cell numbers appeared to increase only in the ileum.

Conclusion

At least in rats, these data demonstrate an earlier essential role for PYY in gut hormone regulation after RYGB. We understand that PYY contributes to GLP-1 and GIP release and there must be the existence of enteroendocrine communication routes between the distal and proximal small intestine.

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13. https://doi.org/10.1056/NEJMoa1401329.CrossRefPubMedPubMedCentral

Zhou J, Hao Z, Irwin N, et al. Gastric inhibitory polypeptide (GIP) is selectively decreased in the roux-limb of dietary obese mice after RYGB surgery. PLoS One. 2015;10(8):e0134728. https://doi.org/10.1371/journal.pone.0134728.CrossRefPubMedPubMedCentral

Shah M, Law JH, Micheletto F, et al. Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes. 2014;63(2):483–93. https://doi.org/10.2337/db13-0954.CrossRefPubMedPubMedCentral

Chambers AP, Jessen L, Ryan KK, et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology. 2011;141(3):950–8. https://doi.org/10.1053/j.gastro.2011.05.050.CrossRefPubMedPubMedCentral

Mokadem M, Zechner JF, Margolskee RF, et al. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab. 2013;3(2):191–201. https://doi.org/10.1016/j.molmet.2013.11.010.CrossRefPubMedPubMedCentral

Ye J, Hao Z, Mumphrey MB, et al. GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am J Physiol Regul Integr Comp Physiol. 2014;306(5):352–62. https://doi.org/10.1152/ajpregu.00491.2013.CrossRef

Ramracheya RD, McCulloch LJ, Clark A, et al. PYY-dependent restoration of impaired insulin and glucagon secretion in type 2 diabetes following Roux-en-Y gastric bypass surgery. Cell Rep. 2016;15(3):944–50. https://doi.org/10.1016/j.celrep.2016.03.091.CrossRefPubMedPubMedCentral

Schmidt JB, Pedersen SD, Gregersen NT, et al. Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial. Int J Obes. 2016;40(2):281–90. https://doi.org/10.1038/ijo.2015.162.CrossRef

Taylor IL. Distribution and release of peptide YY in dog measured by specific radioimmunoassay. Gastroenterology. 2008;88(3):731–7. https://doi.org/10.1016/0016-5085(85)90144-1.CrossRef

10.

Gu N, Tsuda M, Matsunaga T, et al. Glucose regulation of dipeptidyl peptidase IV gene expression is mediated by hepatocyte nuclear factor-1alpha in epithelial intestinal cells. Clin Exp Pharmacol Physiol. 2008;35(12):1433–9. https://doi.org/10.1111/j.1440-1681.2008.05015.x.CrossRefPubMed

11.

Guida C, McCulloch LJ, Godazgar M, et al. Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY. Diabetes Obes Metab. 2018;20(3):571–81. https://doi.org/10.1111/dom.13113.CrossRefPubMed

12.

Van den Hoek AM, Heijboer AC, Corssmit EP, et al. PYY 3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes. 2004;53(8):1949–52. https://doi.org/10.2337/diabetes.53.8.1949.CrossRefPubMed

13.

Allen JM, Fitzpatrick ML, Yeats JC, et al. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion. 1984;30:255–62. https://doi.org/10.1159/000199117.CrossRefPubMed

14.

Chandarana K, Gelegen C, Elaine E, et al. Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol Metab. 2013;2(3):142–52. https://doi.org/10.1016/j.molmet.2013.03.001.CrossRefPubMedPubMedCentral

15.

Bohorquez DV, Liddle RA. Axon-like basal processes in enteroendocrine cells: characteristics and potential targets. Clin Transl Sci. 2011;4(5):387–91. https://doi.org/10.1111/j.1752-8062.2011.00299.x.CrossRefPubMedPubMedCentral

16.

Vannan DT, Bomhof MR, Reimer RA. Comparison of glucose and satiety hormone response to oral glucose vs two mixed-nutrient meals in rats. Front Nutr. 2018;5:89. https://doi.org/10.3389/fnut.2018.00089.CrossRefPubMedPubMedCentral

17.

Yu H, Zheng X, Zhang Z. Mechanism of Roux-en-Y gastric bypass treatment for type 2 diabetes in rats. J Gastrointest Surg. 2013;17(6):1073–83. https://doi.org/10.1007/s11605-013-2188-3.CrossRefPubMedPubMedCentral

18.

Camacho-Ramírez A, Almorza-Gomar D, Díaz-Gómez A, et al. The histomorphometric parameters of endocrine pancreas after bariatric surgery in healthy animal models. Tissue Cell. 2019;57:78–83. https://doi.org/10.1016/j.tice.2019.02.008.CrossRefPubMed

19.

Ndong M, Uehara M, Katsumata S, et al. Effects of oral administration of Moringa oleifera Lam on glucose tolerance in Goto-Kakizaki and Wistar rats. J Clin Biochem Nutr. 2007;40(3):229–33. https://doi.org/10.3164/jcbn.40.229.CrossRefPubMedPubMedCentral

20.

Kashyap SR, Daud S, Kelly KR, et al. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes. 2010;34:462–71. https://doi.org/10.1038/ijo.2009.254.CrossRef

21.

Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98(11):4391–9. https://doi.org/10.1210/jc.2013-2538.CrossRefPubMed

22.

Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243(1):108–14. https://doi.org/10.1097/01.sla.0000183349.16877.84.CrossRefPubMedPubMedCentral

23.

Korner J, Bessler M, Inabnet W, et al. Exaggerated GLP-1 and blunted GIP secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007;3(6):597–601. https://doi.org/10.1016/j.soard.2007.08.004.CrossRefPubMedPubMedCentral

24.

Yan W, Polidori D, Yieh L, et al. Effects of meal size on the release of GLP-1 and PYY after Roux-en-Y gastric bypass surgery in obese subjects with or without type 2 diabetes. Obes Surg. 2014;24(11):1969–74. https://doi.org/10.1007/s11695-014-1316-9.CrossRefPubMed

25.

Harvey EJ, Arroyo K, Korner J, et al. Hormone changes affecting energy homeostasis after metabolic surgery. Mt Sinai J Med. 2010;77(5):446–65. https://doi.org/10.1002/msj.20203.CrossRefPubMed

26.

Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740–8. https://doi.org/10.1007/s11695-012-0622-3.CrossRefPubMedPubMedCentral

27.

Meirelles K, Ahmed T, Culnan DM, et al. Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg. 2009;249(2):277–85. https://doi.org/10.1097/SLA.0b013e3181904af0.CrossRefPubMedPubMedCentral

28.

Østoft SH, Bagger JI, Hansen T, et al. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young—type 2 and type 3. Diabetes. 2014;63(8):2838–44. https://doi.org/10.2337/db13-1878.CrossRefPubMed

29.

Eissele R, Goke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Investig. 1992;122(4):283–91. https://doi.org/10.1111/j.1365-2362.1992.tb01464.x.CrossRef

30.

Mortensen K, Christensen LL, Holst JJ, et al. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept. 2003;114(2-3):189–96. https://doi.org/10.1016/S0167-0115(03)00125-3.CrossRefPubMed

31.

Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol. 2009;587:27–32. https://doi.org/10.1113/jphysiol.2008.164012.CrossRefPubMed

32.

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39. https://doi.org/10.1152/physrev.00034.2006.CrossRefPubMed

33.

Wu Q, Xiao Z, Cheng Z, et al. Changes of blood glucose and gastrointestinal hormones 4 months after Roux-en-Y gastric bypass surgery in Chinese obese type 2 diabetes patients with lower body mass index. J Diabetes Investig. 2012;4(2):214–21. https://doi.org/10.1111/jdi.12005.CrossRefPubMedPubMedCentral

34.

Manning S, Batterham RL. The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on. Annu Rev Physiol. 2014;76:585–608.CrossRef

35.

Goumain M, Voisin T, Lorinet AM, et al. Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon. Biochem Biophys Res Commun. 1998;247:52–6. https://doi.org/10.1006/bbrc.1998.8647.CrossRefPubMed

36.

Bohórquez DV, Samsa LA, Roholt A, et al. An enteroendocrine cell–enteric glia connection revealed by 3D electron microscopy. PLoS One. 2014;9(2):e89881. https://doi.org/10.1371/journal.pone.0089881.CrossRefPubMedPubMedCentral

37.

Pironi L, Stanghellini V, Miglioli M, et al. Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology. 1993;105(3):733–9. https://doi.org/10.1016/0016-5085(93)90890-O.CrossRefPubMed

Title: The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats
Authors: Alonso Camacho-Ramírez
J. Arturo Prada-Oliveira
Antonio Ribelles-García
David Almorza-Gomar
Gonzalo M. Pérez-Arana
Publication date: 01-02-2020
Publisher: Springer US
Keywords: Insulins
Insulins
Published in: Obesity Surgery / Issue 2/2020
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-019-04239-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats

Abstract

Aims

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Biography: Maurizio De Luca

Response to “Letter to the Editor” in regard to the article: “Bariatric Surgery After Previous Antireflux Surgery Without Takedown of The Previous Fundoplication: A Prospective Study”

Preoperative Endoscopic Findings in Veterans Undergoing Bariatric Surgery: Prevalence and Predictors of Barrett’s Esophagus

Resting Energy Expenditure and Organ-Tissue Body Composition 5 Years After Bariatric Surgery

Roux-en-Y-Bariatric Surgery Reduces Markers of Metabolic Syndrome in Morbidly Obese Patients

Effects of bariatric surgery in different obesity phenotypes: Tehran Obesity Treatment Study (TOTS)